Chinese biopharmaceutical company Mabwell (SH:688062) announced on Friday that its wholly-owned subsidiary T-mab has entered into an agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection (R&D code: 8MW0511).

Under the terms of the agreement, Mabwell will grant Qilu Pharmaceutical exclusive rights to develop, manufacture, improve, utilise and commercialise the licensed product in the Greater China (including Chinese Mainland, Hong Kong, Macau and Taiwan). T-mab can obtain a total of up to CNY500m of upfront payment and sales milestone payment, and royalty of up to double-digit percentage of net sales of licensed product.

Albipagrastim alfa for Injection is a recombinant (yeast-secreted) human serum albumin/human granulocyte-colony stimulating factor (I) fusion protein for Injection. It is indicated to reduce the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.